SEARCH

SEARCH BY CITATION

Keywords:

  • RCAS 1;
  • tumor-associated antigen;
  • pancreatic carcinoma;
  • immunohistochemical analysis;
  • prognostic factor

Abstract

  1. Top of page
  2. Abstract
  3. PATIENTS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a recently identified human tumor-associated antigen expressed on various cancer cells. It is thought that tumor cells evade immune surveillance by expression of RCAS1, which induces apoptotic cell death in receptor-positive immune cells. The purpose of our study was to investigate the relation between RCAS1 expression and the clinicopathological variables and clinical outcome in patients with pancreatic adenocarcinoma. Immunohistochemical analysis for RCAS1 was performed on paraffin-embedded specimens of 80 patients (mean age, 62 years) who underwent surgical resection for pancreatic adenocarcinoma. Of the 80 specimens, 77 (96%) were positive for RCAS1. No significant correlation was found between RCAS1 expression and age, gender, depth of invasion, tumor diameter, surgical margin, lymphatic invasion, venous invasion or histopathological grading. Borderline correlations between RCAS1 expression were noted for lymph node metastasis and stage (p = 0.0608 and 0.0934, respectively). RCAS1 expression was very frequently observed and the survival of patients with high RCAS1 expression was significantly shorter than that of those with low expression (p = 0.0012). Multivariate analysis using the Cox regression model indicated that high RCAS1 expression was an independent prognostic factor (risk ratio, 3.090; p = 0.0090). These results suggested that RCAS1 might be a significant tumor marker for pancreatic adenocarcinoma and an unfavorable predictor for prognosis of patients who have undergone surgical resection. © 2002 Wiley-Liss, Inc.

Pancreatic cancer has a very poor prognosis and is one of the most common malignancies.1 Tumor resection is performed in 9–36% of patients and the 5-year survival rate of patients who have undergone resection is 19–24%.2, 3 Many attempts have been made to improve the outcome of patients' survival. Recently, significant improvements in survival have been reported compared to the survival expected from series in the 1980s.4, 5, 6, 7, 8, 9 The mechanisms responsible for the aggressiveness of this disease are not completely understood, therefore, it is very important to find novel molecular markers that are expressed frequently and predominantly in pancreatic cancer. Furthermore, the identification of factors that significantly correlate with clinicopathological features or poor prognosis is of importance in selecting patients who would benefit from radical treatment and to understand the biological characteristics of the disease.

A number of biologic markers that specifically predict the progression and prognosis of pancreatic cancer have been reported, including the K-ras oncogene,10, 11, 12 tumor suppressor DPC4,13, 14, 15, 16 and vascular endothelial growth factor (VEGF).17 Recently, the human tumor-associated antigen RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) has been recognized as another important biological marker expressed on a variety of human cancer cells. This cell membrane molecule was first identified by a mouse monoclonal antibody (22-1-1 antibody) against a human uterine adenocarcinoma cell line, Siso,18 and has been found previously to be a significant prognostic factor not only in cervical cancer but also in non small-cell lung carcinomas.19, 20, 21 Although it has been reported that RCAS1 is also expressed in pancreatic adenocarcinoma cells,22 the prognostic significance of its expression in pancreatic cancer has not been examined to date. As expression of RCAS1 induces apoptotic cell death of receptor-positive immunocytes,23 it has been suggested that upregulation of RCAS1 may play an important role in tumor progression by enabling cancer cells to evade immune surveillance, hence RCAS1 might represent a highly significant prognostic factor distinct from other known factors. The purpose of our study was therefore to perform an immunohistochemical analysis of RCAS1 expression in a cohort of patients with pancreatic adenocarcinoma and to investigate its relationship to clinicopathological variables and prognosis.

PATIENTS AND METHODS

  1. Top of page
  2. Abstract
  3. PATIENTS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

Patients and Tissue Specimens

Surgically resected specimens from 80 patients with pancreatic adenocarcinomas and 7 patients with chronic pancreatitis were studied. All patients underwent surgical resection between 1992 and 1999 in the Second Department of Surgery at the Hokkaido University School of Medicine, the Department of Surgery, Teinekeijinkai Hospital and the Department of Surgery, Hokkaido Gastroenterology Hospital. Among the 80 patients with cancer, 61 patients underwent pancreaticoduodenectomy (Whipple operation), 14 patients underwent distal pancreatectomy and 5 patients underwent total pancreatectomy and all patients received extended radical lymphadenectomy. Of the 23 patients with positive portal vein invasion, 17 patients received portal vein resection. Pancreatic resection was not performed in patients presenting with distant site metastases. Any cases of cystadenocarcinoma or mucin-producing carcinoma were excluded from our study. None of these patients received either radiation or chemotherapy. Pancreatic adenocarcinoma tissues were obtained from 45 men and 35 women with a mean age of 62 years (range 31–83). Median duration of follow-up was 19.8 months (range 3.1–98.0) and 60 patients (75%) died during the follow-up period. All specimens were fixed in 10% formalin and embedded in paraffin wax. Unstained 4-μm sections were then cut from paraffin blocks for immunohistochemical analysis. Histological classification of tumors was based on the World Health Organization criteria. All tumors were staged according to the pTNM pathological classification of the UICC (International Union Against Cancer).24 Seventeen of the tumors were classified as Stage II, 37 as Stage III and 26 as Stage IVA tumors. Thirty of 80 patients had positive resection margin for carcinoma evaluated microscopically (Table I).

Table I. Clinical Characteristics of the Patients with Pancreatic Adenocarcinoma
CharacteristicNumber of cases
Age (year)
 Mean62
 Median63
 Range31–83
Gender
 Male/female45/35
Depth of invasion
 T24
 T350
 T426
Lymph node metastasis
 Negative/positive23/57
Stage
 II17
 III37
 IVA26
Histopathological Grading
 G132
 G240
 G38
Lymphatic invasion
 Negative/positive13/67
Venous invasion
 Negative/positive32/48
Tumor diameter (cm)
 Mean3.7
 Median3.2
 Range1.2–13.0
Surgical margin
 Negative/positive50/30

Immunohistochemical Examination

For immunohistochemical analysis, formalin-fixed and paraffin-embedded specimens were deparaffinized in xylene and dehydrated through a graded series from ethanol to water. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide solution for 10 min. Specimens were washed in phosphate-buffered saline (PBS pH 7.4) twice and incubated with a protein blocking agent (10% normal goat serum) for 5 min. The primary antibody (anti-RCAS1 mouse monoclonal antibody, Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) was applied at 1:500 dilution and specimens were incubated overnight at 4°C. After 3 additional washes, a biotinylated goat antibody to mouse immunoglobulin (Histofine Simple Stain MAX PO (MULTI); Nichirei Corporation, Tokyo, Japan) was applied at room temperature for 30 min. All reagents were washed in PBS three times and incubated with peroxidase-conjugated streptavidin at room temperature for 30 min. The immunohistochemical reactions were developed in freshly prepared 3,3′-diaminobenzidine tetrahydrochloride (Histofine Simple stain DAB Solution; Nichirei Corporation, Tokyo, Japan) for approximately 15 min and washed in distilled water. Sections were counterstained with hematoxylin for 1 min and mounted in Permount. For negative controls, we used 10% normal mouse serum as the primary antibody.

We selected sections that contained the deepest site in each tumor and counted RCAS1 positive cells with a microscopic field of ×400. Five areas containing highest density of reactive cells were evaluated in each case and the mean percentage of cancer cells with positive staining for RCAS1 was determined. Tissue sections with <5% reactive tumor cells were considered negative and those with 5–25%, 25% to 50% and >50% reactive cells were defined as 1+, 2+ and 3+, respectively. The 25% level was the most significant prognostic effect in overall survival. Therefore, we defined 25% as the cutoff for “low” (−/1+) and “high” (2+/3+) expression. Three investigators of our study independently evaluated the immunohistochemical labeling of all specimens, without knowledge of the patients' background or outcome. Immunoreactivity in each section was represented by the median scores evaluated by 3 investigators.

Statistical Analysis

The correlation of RCAS1 immunoreactivity with patients' clinicopathological variables was analyzed by the chi-square test or Fisher's exact test. The Kaplan-Meier method was used to estimate overall survival. Survival differences according to RCAS1 expression were analyzed by the log-rank test. The influence of variables on survival was assessed using Cox univariate and multivariate regression analysis. The risk ratio and its 95% confidence interval were recorded for each marker. Probability values of less than 0.05 were considered statistically significant in all of the analysis. All analysis was performed with statistical software (StatView version 5.0; SAS Institute Inc., Cary, NC).

RESULTS

  1. Top of page
  2. Abstract
  3. PATIENTS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

RCAS1 Expression

Among 80 pancreatic adenocarcinoma specimens, 77 cases (96%) were positive for RCAS1. RCAS1 expression was defined as negative in 3 cases, 1+ in 13 cases, 2+ in 13 cases and 3+ in 51 cases. Patients were classified into 2 groups according to RCAS1 expression. Sixty-four cases (80%) scored 2+ or 3+ were classified as RCAS1 high expression and remainder as low expression. High expression of RCAS1 was found in 11/17 cases (64.7%) of Stage II, 30/37 (81.1%) of Stage III and 23/26 (88.5%) of Stage IVA. RCAS1 was detected both in the cytoplasm and on the plasma membranes of cancer cells, however no reactivity was observed in normal pancreatic cells. (Fig. 1a,b). In all chronic pancreatitis specimens, the ductal cells exhibited no reactivity for RCAS1.

thumbnail image

Figure 1. Immunohistochemical staining for RCAS1 in pancreatic cancer. RCAS1-negative specimen. (a) Strong RCAS1 staining both in the cytoplasm and on the membrane of cancer cells in a positive specimen. More than 50% of reactive tumor cells were defined as 3+. (b) Scale bars = 100 μm.

Download figure to PowerPoint

Correlations between RCAS1 expression and various clinicopathological features are summarized in Table II. Borderline correlations between RCAS1 expression were noted for lymph node metastasis and stage (p = 0.0608 and 0.0934, respectively). No significant correlation, however, was found between RCAS1 expression and age, gender, depth of invasion, tumor diameter, surgical margin, lymphatic invasion, venous invasion or histopathological grading.

Table II. Association between RCAS1 Expression and Clinicopathological Variables
VariablesNumber of casesRCAS1p-value1
Low (−/1+) (n = 16)High (2+/3+) (n = 64)
  • 1

    The p value was calculated by χ-square test.

Age (year)
 <65477400.1730
 ≥6533924
Gender
 Male4511340.2598
 Female35530
Depth of invasion
 T24220.1768
 T3, T4761462
Lymph node metastasis
 Negative238150.0608
 Positive57849
Stage
 II176110.0934
 III, IVA631053
Histopathological Grading
 G1327250.7321
 G2, G348939
Lymphatic invasion
 Negative13580.1219
 Positive671156
Venous invasion
 Negative326260.8195
 Positive481038
Tumor diameter (cm)
 ≤3.55012380.2482
 >3.530426
Surgical margin
 Negative5012380.2482
 Positive30426

Kaplan-Meier Survival Analysis

Survival curves constructed according to the Kaplan-Meier method are shown in Figures 2 and 3. In 80 patients with pancreatic adenocarcinoma, the survival rates for the patients with high RCAS1 expression were significantly lower than for those with low expression (log-rank test, p = 0.0012; Fig. 2). In selected cases with Stage III and IVA disease (n = 63), the survival rates for patients with high RCAS1 expression were significantly lower than those with low expression (log-rank test, p = 0.0124; Fig. 3).

thumbnail image

Figure 2. Kaplan-Meier analysis for overall survival according to RCAS1 expression in patients with pancreatic adenocarcinoma (log-rank test, p = 0.0012).

Download figure to PowerPoint

thumbnail image

Figure 3. Kaplan-Meier analysis for overall survival according to RCAS1 expression in patients with Stage III and IV pancreatic adenocarcinoma (log-rank test, p = 0.0124).

Download figure to PowerPoint

Univariate Analysis of RCAS1 Expression and Clinicopathologic Variables

Univariate analysis for overall survival using Cox regression analysis identified high RCAS1 expression (p = 0.0023), lymph node metastasis (p = 0.0006), tumor diameter (p = 0.0031) and the surgical margin (p = 0.0019) as significant prognostic predictors. Age, gender, depth of invasion, lymphatic invasion, venous invasion and histopathological grading had no prognostic value (Table III).

Table III. Prognostic Factors in Cox Proportional Hazards Model
VariablesUnivariateMultivariate
Risk ratio95% CIp valueRisk ratio95% CIp value
Age (year)
 ≤65/>651.3180.778–2.2320.3047
Gender
 Male/Female1.2070.721–2.0210.4739
Depth of invasion
 T3, T4/T21.2970.402–4.1830.6634
Lymph node metastasis
 Positive/negative3.1851.645–6.1660.00063.0741.559–6.0600.0012
Histopathological Grading
 G2, G3/G11.1440.681–1.9190.6117
Lymphatic invasion
 Positive/negative1.8210.863–3.8440.1156
Venous invasion
 Positive/negative1.6890.995–2.8650.0520
Tumor diameter (cm)
 >3.5/≤3.52.1801.301–3.6510.00311.8311.075–3.1190.0261
Surgical margin
 Positive/negative2.3161.363–3.9350.00192.0841.199–3.6200.0092
RCAS1
 2+, 3+/−, 1+3.4821.562–7.7640.00233.0901.325–7.2070.0090

Multivariate Analysis of RCAS1 Expression and Clinicopathologic Variables

Multivariate analysis of the same set of patients was performed for RCAS1 expression and pathological predictors for survival time using the Cox regression model. The results indicated that high RCAS1 expression was an independent unfavorable prognostic factor (risk ratio, 3.090; p = 0.0090). Positive lymph node metastasis, tumor diameter (>3.5 cm) and positive surgical margin also had independent prognostic value, with a risk ratio of 3.074 (p = 0.0012), 1.831 (p = 0.0261) and 2.084 (p = 0.0092), respectively (Table III).

DISCUSSION

  1. Top of page
  2. Abstract
  3. PATIENTS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

Tumor cells obtain the ability to evade immune surveillance by several strategies that include lack of adequate T cell costimulation,25, 26 downregulation of cell surface MHC class I expression,27, 28, 29 dysfunction of Fas (CD95/APO1)-mediated apoptosis,30, 31, 32 and secretion of immunosuppressive factors, such as transforming growth factor-β (TGF-β).33 In addition to these mechanisms, it has recently been reported that RCAS1 can act as a ligand for a receptor present on activated human T cells and natural killer (NK) cells that inhibits proliferation and induces apoptotic cell death. It was also demonstrated that apoptosis of tumor-infiltrating lymphocytes was induced around RCAS1 positive tumor cells by using the TUNEL method.20

In our study, immunohistochemical analysis revealed that RCAS1 was expressed very frequently, in 96% (77/80 cases) of pancreatic adenocarcinomas. This incidence of RCAS1 expression in pancreatic adenocarcinoma is the highest among reported carcinomas. Previous immunohistochemical studies reported that RCAS1 was expressed in 87.5% of uterine cervical adenocarcinomas, 66% of uterine endometrial adenocarcinomas, 58.8% of ovarian carcinomas and 87.7% of uterine cervical squamous cell carcinomas.18 In non-gynecological cancers, RCAS1 expression was detected in 47.1–74.2% of lung cancers.20, 21 A significant correlation between RCAS1 expression and poor prognosis has also been found in patients with uterine cervical adenocarcinoma19 and with non small-cell lung carcinoma.20, 21

In previous studies RCAS1 expression has been reported to correlate with neoplastic progression. In uterine cervical squamous cell epithelium, RCAS1 was detected in 82.6% of invasive squamous cell carcinomas, 16.7% of microinvasive carcinomas and 20% of carcinoma in situ. RCAS1, however, was not detected in normal uterine cervix and dysplasias.22 In uterine endometrium, RCAS1 was positive in 26% of normal uterine endometrium, 32% of hyperplasias and 68% of uterine endometrial adenocarcinomas.34 In marked contrast to its high incidence in pancreatic adenocarcinoma, we did not detect RCAS1 expression in normal pancreatic duct cells. Thus it seems likely that RCAS1 might also be relevant to neoplastic progression in pancreatic adenocarcinoma. It will worth investigating RCAS1 expression in other types of pancreatic lesions, such as intraductal neoplasias, to clarify the role of RCAS1 in pancreatic cancer progression.35, 36, 37

Based on its proposed immunosuppressive activity, the high incidence of RCAS1 expression might be one of the mechanisms contributing to the dismal outcome of patients with resected pancreatic cancer. Consistent with this hypothesis, we found that the survival rates for pancreatic cancer patients with high RCAS1 expression were significantly lower than for those with low expression (p = 0.0012). The overall 5-year survival rate was 37.9% for patients in the RCAS1 low expression group, compared to 9% for those in the RCAS1 high expression group. Moreover, multivariate analysis demonstrated that high expression of RCAS1 was an independent unfavorable prognostic factor. These findings support the idea that evasion of cancer cells from immune surveillance by expression of RCAS1 may play an important role in determining the course of the patients with pancreatic adenocarcinoma. Therefore, RCAS1 expression in resected specimens may be a useful index of adjuvant therapy for the patients with a high risk of poor prognosis.

Although RCAS1 is a 40-kDa type II membrane protein with an N-terminal transmembrane segment and a coiled-coil structure in the C-terminal portion that is thought to form oligomers, secretion of a soluble form has been confirmed in culture medium of Siso cells (human uterine adenocarcinoma cell line).18, 23 The RCAS1 antigen has also been detected in vaginal discharge from uterine cervical cancer patients.18 This suggests that detection of RCAS1 in the serum or in the pancreatic juice of the patients with pancreatic cancer might also be useful as a highly specific marker for preoperative diagnosis. Moreover, as a number of different tumor-specific antigens have previously been used for gene targeting of virus vectors38, 39 and for selective therapeutic gene expression through use of their cancer cell-specific promoters,40, 41, 42, 43 the high specificity and frequency of RCAS1 expression in patients with pancreatic adenocarcinoma might similarly enable the use of RCAS1 for cancer gene therapy.

REFERENCES

  1. Top of page
  2. Abstract
  3. PATIENTS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  • 1
    Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76: 16717.
  • 2
    Yamamoto M, Ohashi O, Saitoh Y. Japan Pancreatic Cancer Registry: current status. Pancreas 1998;16: 23842.
  • 3
    Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–95, using the National Cancer Database. J Am Coll Surg 1999;189: 17.
  • 4
    Evans DB, Jessup JM, Colacchio T. Pancreatic cancer surgical practice guidelines. Pancreas Cancer Practice Guideline Committee. Oncology (Huntington) 1997; 11: 10749.
  • 5
    Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G, Scheithauer W. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 2000;82: 98103.
  • 6
    Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared to resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89: 31427.
  • 7
    Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225: 62136.
  • 8
    Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223: 2739.
  • 9
    National Cancer Institute. Annual cancer statistics review 1973–88. NIH Publication No.91-2789. Bethesda, MD: Department of Health and Human Services, 1991.
  • 10
    Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102: 2306.
  • 11
    Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16: 777382.
  • 12
    Kawesha A, Ghaneh P Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89: 46974.
  • 13
    Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996;56: 4904.
  • 14
    Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, et al. DPC4 gene in various tumor types. Cancer Res 1996;56: 252730.
  • 15
    Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271: 3503.
  • 16
    Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156: 3743.
  • 17
    Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88: 223945.
  • 18
    Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996;77: 15019.
  • 19
    Kaku T, Sonoda K, Kamura T, Hirakawa T, Sakai K, Amada S, Ogawa S, Kobayashi H, Nakashima M, Watanabe T, Nakano H. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin Cancer Res 1999;5: 144953.
  • 20
    Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y, Yamanaka H, Matsumura A, Iuchi K, Mori T, Okada M. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000;89: 48893.
  • 21
    Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001;92: 44651.
  • 22
    Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin Cancer Res 1998;4: 151720.
  • 23
    Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5: 93842.
  • 24
    SobinLH, Wittekind Ch, editors. UICC TNM classification of malignant tumors. 5th ed. New York: John Wiley and Sons, Inc., 1997.
  • 25
    Melero I, Bach N, Chen L. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci 1997;60: 203541.
  • 26
    Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer 1999;82: 37784.
  • 27
    Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001;61: 15007.
  • 28
    Goodenow RS, Vogel JM, Linsk RL. Histocompatibility antigens on murine tumors. Science 1985;230: 77783.
  • 29
    Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177: 26572.
  • 30
    Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 1996;2: 13616.
  • 31
    Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274: 13636.
  • 32
    Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998;58: 17419.
  • 33
    Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1. Cancer Res 1992;52: 138692.
  • 34
    Sonoda K, Kaku T, Hirakawa T, Kobayashi H, Amada S, Sakai K, Nakashima M, Watanabe T, Nakano H. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic and malignant uterine endometrium. Gynecol Oncol 2000;79: 4249.
  • 35
    Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57: 17314.
  • 36
    Kozuka S, Sassa R, Taki T, Masamoto K, Nagasawa S, Saga S, Hasegawa K, Takeuchi M. pancreatic duct hyperplasia to carcinoma. Cancer 1979;43: 141828.
  • 37
    Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22: 1639.
  • 38
    Haisma HJ, Pinedo HM, Rijswijk A, der Meulen-Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR, Curiel DT. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999;6: 146974.
  • 39
    Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells vs. autologous mesothelial cells in vitro. Clin Cancer Res 2000;6: 432333.
  • 40
    DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994;116: 20513.
  • 41
    Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995;55: 31059.
  • 42
    Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995;55: 52837.
  • 43
    Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000;7: 51826.